{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:07:08Z","timestamp":1776121628003,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2011,8]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (RCT)<\/jats:p>\n                    <jats:p>Level of Evidence\u20031b<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What\u2019s known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Both dutasteride and finasteride inhibit type 2 5\u03b1\u2010reductase, the dominant form of 5\u03b1\u2010reductase in benign prostatic tissue, making these effective treatments for BPH. In comparison with finasteride, dutasteride has a longer half\u2010life and leads to a greater and more consistent suppression of serum and intraprostatic DHT.<\/jats:p>\n                    <jats:p>EPICS is currently the only prospective, randomized, double\u2010blind study of finasteride vs dutasteride for BPH endpoints conducted for longer than a few months. Over a one\u2010year period, treatment with dutasteride and finasteride led to similar reductions in prostate volume, and improvements in peak urine flow and urinary symptoms associated with BPH in men with an enlarged prostate. Men treated with finasteride and dutasteride also experienced similar rates of adverse events over the course of one year, which suggests that inhibition of both type 1 and type 2 5\u03b1\u2010reductase, resulting in greater DHT suppression than type 2 inhibition alone, does not confer an increase in adverse events. Given the long\u2010term, progressive nature of BPH, the one\u2010year duration of EPICS may limit the potential to observe major differences between dutasteride and finasteride treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To assess the efficacy and safety of dutasteride compared with finasteride in treating men with symptomatic benign prostatic hyperplasia (BPH) for 12 months.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>The Enlarged Prostate International Comparator Study was a multicentre, randomized, double\u2010blind, 12\u2010month, parallel\u2010group study.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Men aged \u226550 years with a clinical diagnosis of BPH received once\u2010daily treatment with dutasteride 0.5\u00a0mg (\n                            <jats:italic>n<\/jats:italic>\n                            = 813) or finasteride 5\u00a0mg (\n                            <jats:italic>n<\/jats:italic>\n                            = 817). After a 4\u2010week placebo run\u2010in period, patients were randomized to receive dutasteride or finasteride for 48 weeks, followed by an optional 24\u2010month, open\u2010label phase, during which patients received dutasteride 0.5\u00a0mg once daily.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The primary endpoint was change in prostate volume, and the secondary endpoints included improvement in American Urological Association Symptom Index (AUA\u2010SI) scores, improvement in maximum urinary flow rate (Q\n                            <jats:sub>max<\/jats:sub>\n                            ) and long\u2010term safety in the 24\u2010month open\u2010label phase.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Both dutasteride and finasteride were effective at reducing prostate volume with no significant difference between the two treatments during the study.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Similar reductions in mean AUA\u2010SI scores and Q\n                            <jats:sub>max<\/jats:sub>\n                            were also observed for men in both treatment groups.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>A similar percentage of adverse events was experienced by patients of both treatment groups, and no new adverse events were reported in the open\u2010label phase.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>\n                            Dutasteride and finasteride, when administered for 12 months, were similarly effective in reducing prostate volume and improving Q\n                            <jats:sub>max<\/jats:sub>\n                            and urinary symptoms associated with BPH in men with an enlarged prostate.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2011.10195.x","type":"journal-article","created":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T10:20:06Z","timestamp":1306923606000},"page":"388-394","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":167,"title":["Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)"],"prefix":"10.1111","volume":"108","author":[{"given":"J. Curtis","family":"Nickel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betsy","family":"Morrill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"Rittmaster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)49698-4"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000052475"},{"key":"e_1_2_8_4_2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guideline on management of benign prostatic hyperplasia","volume":"170","author":"AUA Practice Guidelines Committee","year":"2003","journal-title":"J Urol"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64508-7"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04115.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0022-3565(24)36949-6","article-title":"Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR","volume":"282","author":"Bramson HN","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01905-2"},{"key":"e_1_2_8_9_2","first-page":"1251","article-title":"Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2\u2010year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study","volume":"155","author":"Nickel JC","year":"1996","journal-title":"CMAJ"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030330"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000020356"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00654-2"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00198-2"},{"key":"e_1_2_8_14_2","first-page":"1","article-title":"Efficacy of dutasteride and finasteride for the treatment of benign prostate hyperplasia: results of the 1\u2010year Enlarged Prostate International Comparator Study (EPICS)","volume":"95","author":"Gilling P","year":"2005","journal-title":"BJU Int"},{"issue":"9","key":"e_1_2_8_15_2","first-page":"S31","article-title":"Comparison of clinical trials with finasteride and dutasteride","volume":"6","author":"Nickel JC","year":"2004","journal-title":"Rev Urol"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868040-00008"},{"key":"e_1_2_8_17_2","first-page":"143","article-title":"Dutasteride: an evidence\u2010based review of its clinical impact in the treatment of benign prostatic hyperplasia","volume":"1","author":"Thomson A","year":"2005","journal-title":"Core Evidence"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115574"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115954"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210223271706"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2008.01.016"},{"key":"e_1_2_8_22_2","volume-title":"Avodart (Dutasteride) Soft Gel Capsules [Prescribing Information]","author":"GlaxoSmithKline","year":"2008"},{"key":"e_1_2_8_23_2","volume-title":"Proscar (Finasteride) Tablets [Prescribing Information]","author":"Merck & Co. Inc","year":"2010"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.2174\/156802606776743101"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500931"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030656"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.09.035"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02114-3"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608223350801"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10195.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10195.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:21:41Z","timestamp":1761744101000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10195.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10195.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10195.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.12752956.14025054","asserted-by":"object"}]},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"2011-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}